Novo Nordisk A/S ADR buy The Goldman Sachs Group, Inc.
Start price
30.05.24
/
50%
€123.00
Target price
30.05.25
€144.02
Performance (%)
-49.11%
End price
31.05.25
€62.60
Summary
This prediction ended on 31.05.25 with a price of €62.60. The BUY prediction by The_Goldman_Sachs_Gr for Novo Nordisk A/S ADR performed very badly with a performance of -49.11%. The_Goldman_Sachs_Gr has a follow-up prediction for Novo Nordisk A/S ADR where he still thinks Novo Nordisk A/S ADR is a Buy. Dividends of €1.56 are taken into consideration when calculating the performance. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Novo Nordisk A/S ADR | 7.614% | 7.614% | -31.701% |
| iShares Core DAX® | -1.673% | 2.237% | 16.344% |
| iShares Nasdaq 100 | -1.346% | 0.290% | 3.851% |
| iShares Nikkei 225® | -1.529% | 5.863% | 18.286% |
| iShares S&P 500 | -1.702% | 0.697% | 1.755% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $156.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
In the thread Trading Novo Nordisk A/S ADR
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by The_Goldman_Sachs_Gr for Novo Nordisk A/S ADR
Novo Nordisk A/S ADR
Start price
Target price
Perf. (%)
€42.70
28.11.25
28.11.25
€46.61
28.11.26
28.11.26
24.12%
22.01.26
22.01.26
